Larvol Delta - ALKtyrosine-kinase-inhibitor-resistance-due-to-acquired-MET-amplification-in-ALKfusion-positive-advanced-NSCLC-effectively-treated-by-lorlatinibvebreltinib-combination-a-case-report-and-literature-review

vebreltinib (APL-101) - Apollomics

Xalkori (crizotinib) - Pfizer

Lorbrena (lorlatinib) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42170281

Dahong Liu; Peng Song; Yi Liu

May 23, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next